Related Experiment Videos
Scoring a bull's-eye against cancer genome targets
1CRC Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, Surrey, UK. paulw@icr.ac.uk
Abstract:
New anticancer drugs are increasingly targeted to specific abnormalities in the sequence and expression of a series of genes that operate in a stepwise, combinatorial manner to drive the progression of human cancer. These new-generation molecular therapeutics are expected to be more effective and less toxic than the broadly antiproliferative cytotoxic drugs of the previous era, which still dominate medical treatment of cancer today. Molecular and genomic technologies, particularly the availability of the human genome sequence and the ongoing sequencing of cancer genomes, are now having a major impact on target discovery and validation. Over the past year, the progress of three novel anticancer agents in particular (Herceptin, Glivec and Iressa) has exemplified the potential utility of innovative molecular therapeutics in the clinic. Drugs acting on a range of new genome-based molecular targets are now in preclinical and clinical development.
Insights
New anticancer drugs target specific genetic abnormalities for more effective and less toxic cancer treatment. Advances in genomic technologies are driving the development of innovative molecular therapeutics with promising clinical results.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Current cancer treatments often involve broadly antiproliferative cytotoxic drugs.
- Cancer progression is driven by stepwise, combinatorial genetic abnormalities.
- Molecular and genomic technologies are revolutionizing cancer research.
Purpose of the Study:
- To highlight the shift towards targeted anticancer therapies.
- To discuss the impact of genomic technologies on drug discovery.
- To showcase the clinical progress of novel molecular therapeutics.
Main Methods:
- Review of recent advancements in anticancer drug development.
- Analysis of the role of gene sequencing in identifying therapeutic targets.
- Evaluation of clinical data for emerging molecular therapeutics.
Main Results:
- Three novel anticancer agents (Herceptin, Glivec, Iressa) demonstrate significant clinical utility.
- Genomic technologies are crucial for identifying and validating new molecular targets.
- A new generation of genome-based molecular drugs is advancing through development.
Conclusions:
- Targeted molecular therapeutics offer improved efficacy and reduced toxicity compared to traditional chemotherapy.
- The integration of genomics is accelerating the development of personalized cancer treatments.
- Continued research in molecular oncology promises further breakthroughs in cancer therapy.